Growth Inhibition of CD20-positive B Lymphoma Cell Lines by IDEC-C2B8 Anti-CD20 Monoclonal Antibody

Overview

Journal Jpn J Cancer Res

Specialty Oncology

Date 1998 Sep 17

PMID 9738982

Citations 15

Authors

H Taji

Y Kagami

Y Okada

M Andou

Y Nishi

H Saito

M Seto

Y Morishima

Affiliations

Soon will be listed here.

Abstract

Treatment with IDEC-C2B8 (C2B8), the chimeric anti-CD20 antibody, was shown in a phase I-II study to be very effective for the treatment of low-grade B-cell lymphoma, in contrast to the results of most previous immunotherapies with monoclonal antibodies. In a study designed to elucidate the reason for this efficacy, two cell lines derived from lymphomas with BCL2 gene rearrangement (SU-DHL-4 and SU-DHL-6) showed remarkable growth inhibition and cell-death, and two other cell lines derived from a diffuse lymphoma (RC-K8) and a mantle cell lymphoma (SP-49) showed moderate growth inhibition, but neither a CD20 weakly positive cell line (NALL-1) nor a negative cell line (MOLT-4) showed any growth inhibition. An examination of the intensity of cell-surface CD20 expression showed no correlation between intensity and degree of growth inhibition among the four cell lines showing growth inhibition. Morphological examination revealed condensed and fragmented nuclei and budding of the plasma membrane, both characteristic of apoptosis, with some cells in these cell lines showing growth inhibition by C2B8. Such apoptosis was also confirmed by flow cytometric analysis, suggesting that, at least in part, apoptosis plays a role in this growth inhibition. This growth-inhibitory mechanism may thus account for the effectiveness of C2B8 antibody therapy.

Citing Articles

Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma.

Wong J, Stuhlmiller T, Giffin L, Lin C, Bigi R, Zhao J Proc Natl Acad Sci U S A. 2019; 116(33):16541-16550.

PMID: 31346082 PMC: 6697815. DOI: 10.1073/pnas.1903991116.

Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others.

Kobayashi H, Matsunaga Y, Uchiyama Y, Nagura K, Komatsu Y Cancer Med. 2013; 2(2):130-43.

PMID: 23634281 PMC: 3639652. DOI: 10.1002/cam4.60.

Phase II study of CHOP-GR therapy in diffuse large B-cell lymphoma.

Takemura S, Tomita N, Koharazawa H, Fujimaki K, Harano H, Hyo R Int J Hematol. 2012; 96(2):241-6.

PMID: 22684897 DOI: 10.1007/s12185-012-1119-5.

Biological activity of anti-CD20 multivalent HPMA copolymer-Fab' conjugates.

Johnson R, Kopeckova P, Kopecek J Biomacromolecules. 2012; 13(3):727-35.

PMID: 22288884 PMC: 3299848. DOI: 10.1021/bm201656k.

Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy.

Ohishi W, Chayama K Clin Exp Nephrol. 2011; 15(5):634-640.

PMID: 21629993 DOI: 10.1007/s10157-011-0464-7.

References

Maloney D, Liles T, Czerwinski D, Waldichuk C, Rosenberg J, Grillo-Lopez A . Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994; 84(8):2457-66. View

Grossbard M, Press O, Appelbaum F, Bernstein I, Nadler L . Monoclonal antibody-based therapies of leukemia and lymphoma. Blood. 1992; 80(4):863-78. View

Akao Y, Seto M, Takahashi T, Saito M, UTSUMI K, Nakazawa S . Rearrangements on chromosome 11q23 in hematopoietic tumor-associated t(11;14) and t(11;19) translocations. Cancer Res. 1991; 51(24):6708-11. View

Holder M, Grafton G, Macdonald I, Finney M, Gordon J . Engagement of CD20 suppresses apoptosis in germinal center B cells. Eur J Immunol. 1995; 25(11):3160-4. DOI: 10.1002/eji.1830251126. View

Reff M, Carner K, Chambers K, Chinn P, Leonard J, Raab R . Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994; 83(2):435-45. View

Hiraki S, Miyoshi I, Kubonishi I, Matsuda Y, Nakayama T, Kishimoto H . Human leukemic "null" cell line (NALL-1). Cancer. 1977; 40(5):2131-5. DOI: 10.1002/1097-0142(197711)40:5<2131::aid-cncr2820400523>3.0.co;2-v. View

Bikoue A, George F, Poncelet P, Mutin M, Janossy G, Sampol J . Quantitative analysis of leukocyte membrane antigen expression: normal adult values. Cytometry. 1996; 26(2):137-47. DOI: 10.1002/(SICI)1097-0320(19960615)26:2<137::AID-CYTO7>3.0.CO;2-D. View

Kwak L, Campbell M, Czerwinski D, Hart S, Miller R, Levy R . Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992; 327(17):1209-15. DOI: 10.1056/NEJM199210223271705. View

KERR J, Wyllie A, Currie A . Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972; 26(4):239-57. PMC: 2008650. DOI: 10.1038/bjc.1972.33. View

10.

Epstein A, Marder R, Winter J, Fox R . Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors. J Immunol. 1984; 133(2):1028-36. View

11.

Dyer M, Hale G, Hayhoe F, Waldmann H . Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 1989; 73(6):1431-9. View

12.

Hale G, Dyer M, Clark M, Phillips J, Marcus R, Riechmann L . Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 1988; 2(8625):1394-9. DOI: 10.1016/s0140-6736(88)90588-0. View

13.

Golay J, Clark E, Beverley P . The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol. 1985; 135(6):3795-801. View

14.

Koopman G, Reutelingsperger C, Kuijten G, Keehnen R, Pals S, van Oers M . Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994; 84(5):1415-20. View

15.

Denny T, Stein D, Mui T, Scolpino A, Holland B . Quantitative determination of surface antibody binding capacities of immune subsets present in peripheral blood of healthy adult donors. Cytometry. 1996; 26(4):265-74. DOI: 10.1002/(SICI)1097-0320(19961215)26:4<265::AID-CYTO5>3.0.CO;2-B. View

16.

Tedder T, Forsgren A, Boyd A, Nadler L, Schlossman S . Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol. 1986; 16(8):881-7. DOI: 10.1002/eji.1830160802. View

17.

Sahai Srivastava B, Minowada J . Terminal deoxynucleotidyl transferase activity in a cell line (molt-4) derived from the peripheral blood of a patient with acute lymphoblastic leukemia. Biochem Biophys Res Commun. 1973; 51(3):529-35. DOI: 10.1016/0006-291x(73)91346-6. View

18.

Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F . Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry. 1997; 27(1):1-20. View

19.

Tedder T, Boyd A, Freedman A, Nadler L, Schlossman S . The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol. 1985; 135(2):973-9. View

20.

Hsu F, Caspar C, Czerwinski D, Kwak L, Liles T, Syrengelas A . Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. Blood. 1997; 89(9):3129-35. View